There were no deaths in the CANA100 cohort; 1 death (due to a stroke secondary to protein S deficiency) was reported in the CANA300 cohort, which was not considered by the investigator to be related to the study drug. Here, PROS1 is linked to hyperinsulinemic hypoglycemia, familial, 4.